CCR4遺伝子変異はモガムリズマブ(抗CCR4抗体)治療における成人T細胞性白血病/リンパ腫の良好な予後と関連する<要約> by Yuma Sakamoto
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ABSTRACT 
Adult T-cell leukemia/lymphoma (ATL) has a dismal prognosis.  CCR4 is expressed 
by tumor cells from most ATL patients, so therapeutic antibodies such as mogamulizumab, 
may be effective treatments.  Here, we investigate whether gain-of-function mutations in the 
carboxyl terminus of CCR4, which were observed in 38 (33%) of 116 ATL patients, influence 
overall survival (OS) and response to treatment.  We found no significant differences in OS 
when the whole patient cohort was stratified according to CCR4 mutations.  However, in 
those receiving mogamulizumab, 5-year survival from initiation of treatment in patients with 
(n = 11) or without (n = 31) CCR4 mutations was 72.7% and 26.2%, respectively (P = 0.027).  
In contrast, CCR4 mutations did not influence the outcome of allogeneic hematopoietic stem 
cell transplantation.  Finally, in patients with aggressive-variant ATL, 5-year survival on 
mogamulizumab for patients with (n = 10) or without (n = 28) CCR4 mutations was 80.0% 
and 24.7%, respectively (P = 0.006).  These findings suggest that ATL patients with gain-of-
function CCR4 mutations are especially good responders to mogamulizumab-containing 
treatments.  Thus, we conclude that CCR4 gain-of-function mutations determine sensitivity 
to mogamulizumab therapy in ATL.   
 
 
